Evidence map›Paper›PMID 39564454›Full record

ReviewOncoTargets and therapy2024

The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer.

Xinchao Zhao, Yawen Zheng, Yufeng Wang, Mingyan Zhang, Zhilin Dong, Yanan Liu, Meili Sun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in OncoTargets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. [Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinchao Zhao *Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
Yawen Zheng *Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
Yufeng WangDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
Mingyan ZhangDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
Zhilin DongDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
Yanan LiuDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
Meili SunDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In non-small cell lung cancer (NSCLC), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in up to 30% of all cases, with the most prevalent mutations occurring in codons 12 and 13. The development of

Indexed as

adagrasibresistancesotorasibtargeted therapies

Identifiers

PMID39564454
PMCPMC11575457

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.